Asia-Pacific’s pharmaceutical sector is expected to record 4.2% growth from 2022 to 2027, with China and Japan dominating the sector in terms of value. Generics dominate the regions based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region.
• Compared to the United States and the European Union, Asia-Pacific has unique dynamics accompanied by a highly competitive landscape owing to its complex and diverse regulatory landscape and varying pharma sector infrastructures across each country, impacting innovation in each country.
• Japan’s Ministry of Economy, Trade and Industry (METI) implemented 2 subsidy programs—Program for Promoting Investment in Japan to Strengthen Supply Chains and Program for Strengthening Supply Chains—in 2020 to assist Japanese companies in relocating production back to Japan and Southeast Asian countries.
• A growing population, significant R&D investments, a modernized manufacturing base, and the prevalence of chronic diseases fuel growth in these countries.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
